Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug;55(2):197-204.
doi: 10.1016/j.amepre.2018.03.013. Epub 2018 May 30.

Cervical Cancer Incidence in Young U.S. Females After Human Papillomavirus Vaccine Introduction

Fangjian Guo  1 , Leslie E Cofie  2 , Abbey B Berenson  2
Affiliations

Cervical Cancer Incidence in Young U.S. Females After Human Papillomavirus Vaccine Introduction

Fangjian Guo et al. Am J Prev Med. 2018 Aug.

Abstract

Introduction: Since 2006, human papillomavirus vaccine has been recommended for young females in the U.S. This study aimed to compare cervical cancer incidence among young women before and after the human papillomavirus vaccine was introduced.

Methods: This cross-sectional study used data from the National Program for Cancer Registries and Surveillance, Epidemiology, and End Results Incidence-U.S. Cancer Statistics 2001-2014 database for U.S. females aged 15-34 years. This study compared the 4-year average annual incidence of invasive cervical cancer in the 4 years before human papillomavirus vaccine was introduced (2003-2006) and the 4 most recent years in the vaccine era (2011-2014). Joinpoint regression models of cervical incidence from 2001 to 2014 were fitted to identify the discrete joints (year) that represent statistically significant changes in the direction of the trend after the introduction of human papillomavirus vaccination in 2006. Data were collected in 2001-2014, released, and analyzed in 2017.

Results: The 4-year average annual incidence rates for cervical cancer in 2011-2014 were 29% lower than that in 2003-2006 (6.0 vs 8.4 per 1,000,000 people, rate ratio=0.71, 95% CI=0.64, 0.80) among females aged 15-24 years, and 13.0% lower among females aged 25-34 years. Joinpoint analyses of cervical cancer incidence among females aged 15-24 years revealed a significant joint at 2009 for both squamous cell carcinoma and non-squamous cell carcinoma. Among females aged 25-34 years, there was no significant decrease in cervical cancer incidence after 2006.

Conclusions: A significant decrease in the incidence of cervical cancer among young females after the introduction of human papillomavirus vaccine may indicate early effects of human papillomavirus vaccination.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cervical cancer incidence among women aged 15–24 years, USCS 2001–2014. (A) Any histology. (B) SCC and non-SCC. Notes: Rates are per 1,000,000 and age-adjusted to the 2000 U.S. Standard Population standard. APC, annual percentage change; USCS, U.S. Cancer Statistics; SCC, squamous cell carcinoma.
Figure 2
Figure 2
Age-adjusted incidence rate of invasive cervical cancer by histology in women (25–34 years), USCS 2001–2014. (A) Any histology. (B) SCC and non-SCC. Notes: Rates are per 1,000,000 and age-adjusted to the 2000 U.S. Standard Population standard. USCS, U.S. Cancer Statistics; SCC, squamous cell carcinoma.
See this image and copyright information in PMC

References

    1. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–1056. doi: 10.1016/S1470-2045(10)70230-8. - DOI - PubMed
    1. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364(9447):1757–1765. doi: 10.1016/S0140-6736(04)17398-4. - DOI - PubMed
    1. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915–1927. doi: 10.1056/NEJMoa061741. - DOI - PubMed
    1. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–723. doi: 10.1056/NEJMoa1405044. - DOI - PubMed
    1. Petrosky E, Bocchini JA, Jr, Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64(11):300–304. - PMC - PubMed

Publication types

Substances